AB Science communique une mise à jour sur le calendrier des résultats cliniques
October 10, 2019 02:03 ET
|
AB Science
Paris, 10 octobre 2019, 8h AB Science communique une mise à jour sur le calendrier des résultats cliniques Annonce des résultats dans l’asthme et dans la sclérose en plaques confirmée au T4 2019 AB...
AB Science provides update on masitinib programs timelines
October 10, 2019 02:03 ET
|
AB Science
Paris, October 10, 2019, 8am AB Science provides update on masitinib programs timelines Company is on track to announce data in severe asthma and in MS in 4Q 2019 AB Science SA (NYSE Euronext -...
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2019 et présente un point sur ses activités
September 30, 2019 13:41 ET
|
AB Science
Paris, 30 septembre 2019, 20h Perte nette de 13M€ au premier semestre 2019 Déficit opérationnel de 10,6 M€, soit une réduction des dépenses de 25,5% par rapport au premier semestre 2018...
AB Science today reports its revenues for the first half of 2019 and provides an update on its activities.
September 30, 2019 13:41 ET
|
AB Science
Paris, September 30, 2019, 8pm Net loss of 13M€ in the first half of 2019 Operating loss of -10.6M€, a 25.5% expenses decrease as compared withthe first half of 2018 (14.2M€) Cash position of 2.7M€...
AB Science annouces the success of a private placement
August 19, 2019 14:58 ET
|
AB Science
AB SCIENCE ANNOUNCES THE SUCCESS OF A PRIVATE PLACEMENT EUR 10.0 million raised through a private placement of 2,463,054 new...
AB Science to present at two upcoming conferences in September 2019, the NewsMakers 2019 Healthcare conference and the H.C. Wainwright Healthcare Conference
August 12, 2019 13:08 ET
|
AB Science
Paris, August 12th,2019, 7pm AB Science to present at two upcoming conferences in September 2019, the NewsMakers 2019 Healthcare conference and the H.C. Wainwright Healthcare Conference AB Science...
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
November 07, 2018 16:10 ET
|
Voyager Therapeutics, Inc.
One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and beyond from ongoing Phase 1b trial Recent preclinical results for Huntington’s disease and...
Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
October 16, 2018 07:03 ET
|
Voyager Therapeutics, Inc.
One-time delivery of VY-HTT01 for Huntington’s disease achieves significant reduction of HTT gene expression in deeper tissues and outer layers of the brain of large animals One-time delivery of...
American Airlines to Donate $1M to Answer ALS Foundation
September 20, 2016 15:35 ET
|
American Airlines Group, Inc.
FORT WORTH, Texas, Sept. 20, 2016 (GLOBE NEWSWIRE) -- American Airlines this year will begin a multi-year financial commitment of $1 million to the Answer ALS research project through the Answer ALS...